Skip to main content
Top
Published in: Drugs 17/2008

01-12-2008 | Original Research Article

Early Switch to Oral Treatment in Patients with Moderate to Severe Community-Acquired Pneumonia

A Meta-Analysis

Authors: Zoe Athanassa, Gregory Makris, George Dimopoulos, Dr Matthew E. Falagas

Published in: Drugs | Issue 17/2008

Login to get access

Abstract

Background: Early switch to oral antibacterials is recommended for the treatment of hospitalized patients with community-acquired pneumonia (CAP). However, its efficacy and safety in patients with more severe forms of CAP have not been well established.
Objective: To evaluate early switch to oral treatment in hospitalized patients with moderate to severe CAP.
Methods: Two reviewers independently extracted data from relevant randomized controlled trials (RCTs) with the same total duration of antibacterial treatment in the compared groups (early switch from intravenous to oral and conventional intravenous treatment for the whole duration of therapy).
Results: Six RCTs including 1219 patients fulfilled the criteria for inclusion in the meta-analysis. Treatment success was not different between early switch to oral treatment and intravenous only treatment groups in both intention to treat (odds ratio [OR] 0.76; 95% CI 0.36, 1.59) and clinically evaluable patients (OR 0.92; 95% CI 0.61, 1.39). Mortality and recurrence of CAP were not different (OR 0.81; 95% CI 0.49, 1.33 and OR 1.81; 95% CI 0.70, 4.72, respectively), while duration of hospitalization was shorter (weight mean difference −3.34; 95% CI −4.42, −2.25) and drug-related adverse events were fewer in the early switch group (OR 0.65; 95% CI 0.48, 0.89). Findings were similar in patients with severe CAP.
Conclusions: Early conversion to oral antibacterials seems to be as effective as continuous intravenous treatment in patients with moderate to severe CAP and results in substantial reduction in duration of hospitalization.
Literature
1.
go back to reference Marston BJ, Plouffe JF, File Jr TM, et al. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997; 157: 1709–18 Marston BJ, Plouffe JF, File Jr TM, et al. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997; 157: 1709–18
2.
go back to reference Guest JF, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the United Kingdom. Eur Respir J 1997; 10: 1530–4PubMedCrossRef Guest JF, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the United Kingdom. Eur Respir J 1997; 10: 1530–4PubMedCrossRef
3.
go back to reference Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820–37PubMedCrossRef Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820–37PubMedCrossRef
4.
go back to reference Rello J, Catalan M, Diaz E, et al. Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med 2002; 28: 1030–5PubMedCrossRef Rello J, Catalan M, Diaz E, et al. Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med 2002; 28: 1030–5PubMedCrossRef
5.
go back to reference Feikin DR, Schuchat A, Kokzak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health 2000; 90: 223–9PubMedCrossRef Feikin DR, Schuchat A, Kokzak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health 2000; 90: 223–9PubMedCrossRef
6.
go back to reference Mandell LA, Wunderink RG, Anzueto A, et al., for the Infectious Diseases Society of America-American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: S27–72PubMedCrossRef Mandell LA, Wunderink RG, Anzueto A, et al., for the Infectious Diseases Society of America-American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: S27–72PubMedCrossRef
7.
go back to reference Woodhead M, Blasi F, Ewig S, et al. ERS task force in collaboration with ESCMID. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138–80 Woodhead M, Blasi F, Ewig S, et al. ERS task force in collaboration with ESCMID. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138–80
8.
go back to reference Castro-Guardiola A, Viejo-Rodriguez AL, Soler-Simon S, et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial. Am J Med 2001; 111: 367–74PubMedCrossRef Castro-Guardiola A, Viejo-Rodriguez AL, Soler-Simon S, et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial. Am J Med 2001; 111: 367–74PubMedCrossRef
9.
go back to reference Siegel RE, Halpem NA, Almenoff PL, et al. A prospective randomized study of inpatient IV antibiotics for community-acquired pneumonia: the optimal duration of therapy. Chest 1996; 110: 965–71PubMedCrossRef Siegel RE, Halpem NA, Almenoff PL, et al. A prospective randomized study of inpatient IV antibiotics for community-acquired pneumonia: the optimal duration of therapy. Chest 1996; 110: 965–71PubMedCrossRef
10.
go back to reference Rhew DC, Tu GS, Ofman J, et al. Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis. Arch Intern Med 2001; 161: 722–7PubMedCrossRef Rhew DC, Tu GS, Ofman J, et al. Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis. Arch Intern Med 2001; 161: 722–7PubMedCrossRef
11.
go back to reference Halm EA, Switzer GE, Mittman BS, et al. What factors influence physicians' decision to switch from intravenous to oral antibiotics for community-acquired pneumonia? J Gen Intern Med 2001; 16: 599–605PubMedCrossRef Halm EA, Switzer GE, Mittman BS, et al. What factors influence physicians' decision to switch from intravenous to oral antibiotics for community-acquired pneumonia? J Gen Intern Med 2001; 16: 599–605PubMedCrossRef
12.
go back to reference Moher D, Pham B, Jones A, et al. Does quality of reports of randomized trials affects estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609–13PubMedCrossRef Moher D, Pham B, Jones A, et al. Does quality of reports of randomized trials affects estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609–13PubMedCrossRef
13.
go back to reference Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243–50PubMedCrossRef Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243–50PubMedCrossRef
14.
go back to reference Lim WS, van der Eerden MM, Laing R, et al. Defining community-acquired pneumonia on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377–82PubMedCrossRef Lim WS, van der Eerden MM, Laing R, et al. Defining community-acquired pneumonia on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377–82PubMedCrossRef
15.
go back to reference Yaqub A, Khan Z. Comparison of early intravenous to oral switch amoxicillin/clavulanate with parenteral ceftriaxone in treatment of hospitalized patients with community acquired pneumonia. Pak J Med Sci 2005; 21: 259–66 Yaqub A, Khan Z. Comparison of early intravenous to oral switch amoxicillin/clavulanate with parenteral ceftriaxone in treatment of hospitalized patients with community acquired pneumonia. Pak J Med Sci 2005; 21: 259–66
16.
go back to reference Oosterheert JJ, Bonten MJM, Schneider MM, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community-acquired pneumonia: multicentre randomized trial. BMJ 2006; 333: 1193–8PubMedCrossRef Oosterheert JJ, Bonten MJM, Schneider MM, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community-acquired pneumonia: multicentre randomized trial. BMJ 2006; 333: 1193–8PubMedCrossRef
17.
go back to reference Omidvari K, de Boisblanc BP, Karam G, et al. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir Med 1998; 92: 1032–9PubMedCrossRef Omidvari K, de Boisblanc BP, Karam G, et al. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir Med 1998; 92: 1032–9PubMedCrossRef
18.
go back to reference Norrby SR, Petermann W, Willcox PA, et al. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 1998; 30: 397–404PubMedCrossRef Norrby SR, Petermann W, Willcox PA, et al. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 1998; 30: 397–404PubMedCrossRef
19.
go back to reference Lee RWW, Lindstrom ST. Early switch to oral antibiotics and early discharge guidelines in the management of patients with community-acquired pneumonia. Respirology 2007; 12: 111–6PubMedCrossRef Lee RWW, Lindstrom ST. Early switch to oral antibiotics and early discharge guidelines in the management of patients with community-acquired pneumonia. Respirology 2007; 12: 111–6PubMedCrossRef
20.
go back to reference Capelategui A, Espana PP, Quintana JM, et al. Improvement of process of care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before and after design study. CID 2004; 39: 995–63 Capelategui A, Espana PP, Quintana JM, et al. Improvement of process of care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before and after design study. CID 2004; 39: 995–63
21.
go back to reference Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA 2000; 283: 749–55PubMedCrossRef Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA 2000; 283: 749–55PubMedCrossRef
22.
go back to reference Halm EA, Fine MJ, Kapoor WN, et al. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med 2002; 162: 1278–84PubMedCrossRef Halm EA, Fine MJ, Kapoor WN, et al. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med 2002; 162: 1278–84PubMedCrossRef
23.
go back to reference Kothe H, Bauer T, Marre R, et al. Outcome of CAP: influence of age, residence status, and antimicrobial treatment. Eur Respir J 2008; 32: 139–46PubMedCrossRef Kothe H, Bauer T, Marre R, et al. Outcome of CAP: influence of age, residence status, and antimicrobial treatment. Eur Respir J 2008; 32: 139–46PubMedCrossRef
24.
go back to reference Polic-Vizintin M, Lepee M, Stimac D, et al. Risk of pneumonia reccurence in patients previously hospitalized for pneumonia: a retrospective study. Coll Antropol 2005; 29: 213–9PubMed Polic-Vizintin M, Lepee M, Stimac D, et al. Risk of pneumonia reccurence in patients previously hospitalized for pneumonia: a retrospective study. Coll Antropol 2005; 29: 213–9PubMed
25.
go back to reference Hedlund J, Ortqvist AB, Kalin M, et al. Risk of pneumonia in patients previously treated in hospital for pneumonia. Lancet 1992; 340: 396–7PubMedCrossRef Hedlund J, Ortqvist AB, Kalin M, et al. Risk of pneumonia in patients previously treated in hospital for pneumonia. Lancet 1992; 340: 396–7PubMedCrossRef
26.
go back to reference Lanbeck P, Odenholt I, Riesbeck K. Dicloxacillin and erythromycin at high concentrations increase ICAM-1 expression by endothelial cells: a possible factor in the pathogenesis of infusion phlebitis. J Antimicrob Chemother 2004; 53: 174–9PubMedCrossRef Lanbeck P, Odenholt I, Riesbeck K. Dicloxacillin and erythromycin at high concentrations increase ICAM-1 expression by endothelial cells: a possible factor in the pathogenesis of infusion phlebitis. J Antimicrob Chemother 2004; 53: 174–9PubMedCrossRef
27.
go back to reference Mortensen EM, Coley CM, Singer DE, et al. Causes of death for patients with community-acquired pneumonia: results from the pneumonia patient outcome research team cohort study. Arch Intern Med 2002; 162: 1059–64PubMedCrossRef Mortensen EM, Coley CM, Singer DE, et al. Causes of death for patients with community-acquired pneumonia: results from the pneumonia patient outcome research team cohort study. Arch Intern Med 2002; 162: 1059–64PubMedCrossRef
Metadata
Title
Early Switch to Oral Treatment in Patients with Moderate to Severe Community-Acquired Pneumonia
A Meta-Analysis
Authors
Zoe Athanassa
Gregory Makris
George Dimopoulos
Dr Matthew E. Falagas
Publication date
01-12-2008
Publisher
Springer International Publishing
Published in
Drugs / Issue 17/2008
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/0003495-200868170-00005

Other articles of this Issue 17/2008

Drugs 17/2008 Go to the issue

Adis Drug Evaluation

Ranolazine